Adherence to Cardiovascular Medications: Lessons Learned and Future Directions by Kronish, Ian M. & Ye, Siqin
Adherence to Cardiovascular Medications: Lessons Learned and
Future Directions
Ian M Kronish, MD, MPH and Siqin Ye, MD
Abstract
Approximately 50% of patients with cardiovascular disease and/or its major risk factors have poor
adherence to their prescribed medications. Finding novel methods to help patients improve their
adherence to existing evidence-based cardiovascular drug therapies has enormous potential to
improve health outcomes while potentially reducing health care costs. The goal of this report is to
provide a review of the current understanding of adherence to cardiovascular medications from the
point of view of prescribing clinicians and cardiovascular researchers. Key topics addressed
include: 1) definitions of medication adherence; 2) prevalence and impact of non-adherence; 3)
methods for assessing medication adherence; 4) reasons for poor adherence; and 5) approaches to
improving adherence to cardiovascular medications. For each of these topics, the report seeks to
identify important gaps in knowledge and opportunities for advancing the field of cardiovascular
adherence research.
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Introduction
Modern medicine has been notable for its discovery of numerous medications that improve
health outcomes. For example, since the 1950s, nearly one hundred blood pressure
medications from twelve distinct classes have been developed. Yet, despite the clear benefits
of antihypertensive medications on blood pressure control and cardiovascular outcomes, up
to 50% of patients do not take their blood pressure medications as prescribed and only 50%
of treated individuals reach their blood pressure goals.1 Adherence to other cardiovascular
medications such as statins and antiplatelets is equally poor.1,2 Compared with all of the
resources spent on the development of new drugs, helping patients improve their adherence
to existent cardiovascular drugs has enormous potential for improving health outcomes
while reducing healthcare costs.
The goal of this report is to provide a review of the current understanding of adherence to
cardiovascular medications from the point of view of prescribing clinicians and
cardiovascular researchers. Key topics addressed include: 1) definitions of medication
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adherence; 2) prevalence and impact of non-adherence; 3) methods for assessing adherence;
4) reasons for poor adherence; and 5) approaches to improving adherence to cardiovascular
medications. For each of these topics, the report seeks to identify important gaps in
knowledge and opportunities for advancing the field of cardiovascular adherence research.
Defining Medication Adherence
Medication adherence refers to the extent to which patients take medications in the manner
prescribed by their clinicians.3 For the most part, the term “adherence” has replaced the term
“compliance” in the medical literature. This change in terminology reflects the
contemporary, patient-centered concept of health care in which patients and providers
collaborate on treatment plans, rather than patients unilaterally following physicians’
instructions. There are more precise definitions of adherence that pertain to different aspects
of medication adherence. The first pertains to the day-to-day pill-taking behavior of patients
who are taking a medication at least some of the time. In this case, adherence is defined as
the percentage of pills a patient takes as prescribed. By convention, a cut-point of 80% is
used to categorize adherence to cardiovascular medications into good and poor adherence
groups. A second definition of adherence considers the duration of time a patient remains
engaged with a prescription regimen, even if intermittently, before discontinuing the
medication prematurely and permanently. With this definition, patients are categorized as
non-adherent if they discontinue a medication before a certain time period. Primary non-
adherence refers to a situation in which a patient “discontinues” a medication before even
filling a prescription once.4 More detailed definitions of medication adherence depend on
the method of adherence measurement and will be described in more detail below.
Gaps in Knowledge
Although researchers commonly use a cutpoint of 80% of pills taken as prescribed to define
poor adherence to cardiovascular medications, the optimal cutpoints for categorizing
adherence remain poorly understood. The use of the 80% cutpoint can be traced back to a
small blood pressure treatment trial among 230 steelworkers in which the authors found that
diastolic blood pressure declined significantly only when participants took more than 80%
of their pills.5 While there is strong reason to suspect that the optimal threshold for
adherence may vary between medications as a result of differences in their pharmacokinetic
and pharmacodynamic properties, there has been scant research to identify whether other
thresholds for categorizing adherence to cardiovascular medications are superior.6 It is
conceivable that in some clinical settings, such as the use of anti-platelet agents immediately
after coronary artery stenting, the optimal threshold for defining adherence may be higher
and may even approach 100%. In other settings, such as statin use in patients with low
cardiovascular risk, a clinically relevant threshold for defining adherence may be
considerably lower. Increasing our understanding of the optimal cutpoints for adherence for
cardiovascular medications may lead to a more precise understanding of the scope of the
adherence problem, the population to which adherence interventions should be targeted, and
the scale of resources needed for interventions to improve adherence to specific drug
classes.
Another gap in knowledge in defining adherence pertains to the relevance of more precise
definitions of medication adherence. With the advent of electronic medication monitors that
record the date and time medications are ingested, we can now measure not only the total
number of pills a patient took over a time period, but the extent to which the correct number
of pills were taken each day (referred to as dosing adherence) and the extent to which these
pills were taken during the correct time intervals (referred to as timing adherence). It
remains to be determined how much these more precise definitions of medication adherence
are relevant to understanding the impact of adherence on cardiovascular outcomes
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To date, most definitions of day-to-day adherence presume that adherence is a stable patient
characteristic. Yet, there is evidence that medication adherence may be more accurately
understood as a dynamic process. For example, for some patients who have suffered an
acute coronary syndrome (ACS), the ACS may serve as a teachable moment that leads to
improvements in medication adherence over time. In other post-ACS patients, the stress of
the ACS may lead to a worsening of adherence. Statistical approaches such as latent class
analysis and adaptive statistical methods can be used to determine whether distinct
longitudinal trajectories of adherence (e.g., consistent good adherence versus delayed non-
adherence) are present in a population.7,8 Future studies should assess whether definitions of
adherence that incorporate time-varying patterns can assist efforts to target patient groups
with the most worrisome adherence patterns and guide the most appropriate time points for
personalized interventions.
Prevalence and Impact of Poor Adherence to Cardiovascular Medications
Prevalence
Notwithstanding variability in definitions of adherence, how common is poor adherence to
cardiovascular medications? In a meta-analysis of 20 observational studies involving
376,162 patients, a summary estimate of the prevalence of poor adherence across multiple
drug classes as measured by pharmacy refill data was 43%.1 This is similar to the estimated
prevalence of poor adherence to both cardiovascular and non-cardiovascular medications as
reported by the World Health Organization.9 These percentages represent summary
estimates, and there are substantial differences in adherences to specific cardiovascular
medications, even among those prescribed for the same cardiovascular condition. In the case
of antihypertensives, adherence ranges from a low of 28% for β-blockers to a high of 65%
for angiotensin receptor blockers.10 Adherence also varies depending on whether
medications are prescribed for primary or secondary prevention with primary prevention
typically associated with lower adherence.1 Yet, even in the immediate aftermath of acute
cardiac events, adherence is suboptimal. In a population cohort of 4,591 post-myocardial
infarction (MI) patients, 18% did not fill their cardiac medications even once in the 4
months after discharge from hospital,11 and in a separate cohort of 22,379 post-ACS
patients, 60% discontinued their statin medication within 2 years of hospitalization.12 The
transition from hospitalization to discharge is a period of particularly high risk for
medication errors and non-adherence.13 Even in clinical trial settings where patients are
carefully selected, substantial rates of poor adherence have been documented.6 Hence,
irrespective of differences in how and when adherence is measured, poor adherence to
cardiovascular medications is highly prevalent across patient populations and cardiovascular
drug classes.
Impact
Poor medication adherence has been associated with a number of adverse health impacts. To
begin with, poor adherence is associated with poor control of risk factors such as
hypertension and cholesterol.14 Unfortunately, clinicians are often unaware that poor
adherence underlies the uncontrolled risk factor. This often leads to unnecessary treatment
intensification and the potential for adverse effects of overtreatment when patients suddenly
take their complete regimen.14 Poor adherence is also associated with worse health
outcomes. Rasmussen and colleagues showed that survivors of acute MIs who had poor and
intermediate adherence to statins were at 25% and 12% increased risk of mortality,
respectively, compared to survivors with high adherence.15 Similarly, Spertus and
colleagues showed that patients who prematurely discontinued thienopyridines within 30
days of drug-eluting stent placement were at 9 times increased risk of mortality in the
subsequent year,16 and our study demonstrated that patients who had poor adherence to
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aspirin (took <80% doses correctly) in the month after ACS had nearly twice the risk of
morality or recurrent cardiovascular events in the following year.17 Poor adherence to heart
failure medications has also been associated with increased mortality and heart failure
hospitalizations.18 Thus, patients with poor medication adherence have strong and consistent
associations with worse health outcomes across a range of evidence-based medications and
cardiovascular conditions.
Poor adherence also contributes to health care costs. Although poor adherence leads to lower
medication costs, it can increase non-medication health care costs by causing suboptimal
disease control and increased health care utilization. Using administrative claims data, Sokol
and colleagues estimated the health care costs associated with poor adherence to
hypertension and hypercholesterolemia medications.19 They found that savings from lower
medication costs were offset by increased total medical costs driven in part by decreased
hospitalizations such that poor adherence was associated with higher overall health care
costs. These findings have subsequently been verified in other samples using updated
methodologies.20 This raises the tantalizing possibility that programs to increase medication
adherence may actually provide an opportunity in which investment in health services can
both improve health outcomes and lower costs.
Gaps in Knowledge
Some have questioned the extent to which poor medication adherence directly causes worse
health outcomes or whether the association between the two is spurious. They speculate that
medication adherence is likely a marker of other favorable health behaviors (e.g., adherence
to medical advice in general or to behaviors like exercise and smoking cessation) or
socioeconomic characteristics (e.g., access to health care or social support), such that the
strong associations between medication adherence and outcomes are primarily due to a
“healthy adherer” effect rather than to specific benefits of adhering to a given medication.
Evidence in support of the healthy adherer effect comes from several post-hoc analyses of
randomized controlled trials in which patients who had better adherence to placebo had
better health outcomes than patients who were less adherent to placebo or to a non-harmful
treatment. For example, in the in the Beta Blocker Heart Attack Trial, patients who were
more adherent to placebo had 62% lower odds of mortality than patients who were non-
adherent to placebo within a year of follow-up.21 If this hypothesis is correct, then
interventions that are directed toward increasing adherence to specific medications may not
have the desired effect on health outcomes.
Another possible explanation for the health benefits of medication adherence is that the act
of taking pills may activate a placebo effect. The placebo effect can be defined as a
psychophysiologic effect that is derived from expecting a benefit from treatment.22
Laboratory studies have shown that the receipt of placebo medications can result in
demonstrable biological effects. Moreover, in studies of the impact of adherence to placebo
on health outcomes, adjusting for adherence to other health behaviors like smoking and
exercise do not reliably weaken the strength of the benefit of adherence to placebo.23 These
findings challenge the hypothesis that the benefits of adherence to placebo are due to a
healthy adherer effect and increase the likelihood that increasing adherence can amplify the
biological benefits of the placebo effect.
Additional evidence contrary to the “healthy adherer” hypothesis comes from the
retrospective study by Rasmussen and colleagues.15 They showed that while poor adherence
to statins and renin-angiotensin system inhibitors after MI was associated with increased
adverse events, poor adherence to calcium-channel blockers – a drug class not expected to
have an impact on post-MI prognosis – was not associated with worse outcomes.15 This led
the authors to conclude that adherence to specific medications can have specific effects on
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health outcomes. Future studies examining the association between adherence and health
outcomes should seek to determine whether the strong association between medication
adherence and outcomes is mainly due to drug effect or whether alternative mechanisms
such as healthy adherer or placebo effects play a major role. This can be accomplished by
carefully measuring potential confounders of the relationship between adherence and
outcomes such as health behavior, socioeconomic status, or susceptibility for the placebo
effect.
Approaches to Measuring Medication Adherence
Clinical Judgment
Clinical judgment represents the most common way medication adherence is assessed by
physicians and allied health professionals. Unfortunately, multiple studies have
demonstrated that clinicians are poor at judging the extent to which their patients are taking
their pills.24 Overall, clinicians tend to underestimate the extent of non-adherence in their
practice, likely due to a combination of reasons such as lacking awareness of the high
prevalence of non-adherence, disbelieving that their own patients would not follow their
recommendations, and relying on patient self-reports even though patients often over-report
how well they adhere.
Validated Self-Report Tools
To overcome the inadequacy of relying on clinical judgment, a number of self-report
instruments have been developed to measure medication adherence (Table 1). Some self-
report instruments ask about aspects of non-adherent behavior (e.g., unintentionally
forgetting medications when travelling, intentionally skipping doses when feeling well) over
different time periods.25 Others ask patients to recall the extent to which pills were taken
during specific time periods using a visual analog scale or single-item questions or combine
items asking about the frequency of adherence with items asking about specific adherence
behaviors. The test properties of these instruments are often validated against objective
measures of adherence or against measures of disease control.26 An advantage of these
instruments is that they are generally brief, inexpensive, provide immediate feedback to the
clinician or researcher, and the responses may help identify some correctable misperceptions
about adherence to medications. However, despite their relative simplicity, these scales are
at best moderately related to objective measures of adherence and are limited by social
desirability and other recall biases. These biases lead the instruments to overestimate how
well patients adhere by approximately 10–20% as compared to objective measures.27
Despite their limitations, clinicians can learn some important lessons from validated self-
report instruments. First, in an attempt to decrease over-reporting, many of these tools are
prefaced by a script that seeks to normalize non-adherent behavior. Clinicians might apply
this strategy when asking whether their own patients have missed doses. In addition,
counterintuitively, studies suggest that questionnaires that ask about adherence over a
medium to long-term time frame (e.g., two-weeks or longer) are more accurate than those
that ask about the most recent period (< 1 week).28 Hence, to get a more accurate estimate,
clinicians should ask about non-adherence more generally rather than focusing on adherence
on the day or two preceding the clinic visit. Finally, clinicians should be mindful that self-
reports likely represent over-reports of true adherence and hence patients who admit to even
some non-adherence behavior should be carefully assessed for potential adherence
problems.
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Given the high potential for recall bias with self-report measures of adherence, a number of
objective measures of medication adherence have been developed. Direct measures of
medication intake via drug levels (e.g., digoxin) are not available for most cardiovascular
medications. Even when available, they are highly dependent on the pharmacologic
properties of the medication and represent imprecise measures of the intensity or duration of
pill-taking. Hence, clinicians and researchers must rely on indirect measures of objective
medication adherence.
Indirect measures of medication adherence include physiologic or biologic markers, pill
counts, pharmacy refill data, and electronic measurement (Table 1). The advantages and
disadvantages of these approaches are described below. Physiologic or biologic markers of
adherence to cardiovascular medications include blood pressure in the case of
antihypertensives, LDL levels in the case of statins, and platelet function tests in the case of
aspirin and other anti-platelet agents. Similar to relying on drug levels, while potentially
helpful for identifying patients who are non-adherent, such markers depend on the
pharmacology of the medication and the biology of the patient. In many cases, these tests
cannot distinguish whether a patient is resistant to the drug for biological reasons or whether
the patient is truly non-adherent.
Pill counts are often used in research settings, but are often impractical for clinical settings
especially if clinicians are expected to count pills for multiple medications. The common
patient practice of stockpiling medications at home challenges the accuracy of pill counts.
Further, patients may discard pills prior to visits at which they expect pills to be counted
which may lead to overestimates of adherence. Pill counts also do not provide information
as to whether pills were taken at the time intervals prescribed.
Pharmacy refill data have become increasingly accessible from pharmacy benefit managers
such as Medicare Part D and from health systems with closed pharmacy systems such as the
Veterans Administration. Refill data can be used to calculate metrics such as the proportion
of days covered by medication (PDC, defined as the number of pills dispensed between the
first and last refill divided by the number of days between refills) or the time to
discontinuation of a medication (defined as the length of time prior to a large gap in
medication use).3 One important advantage of refill data is that they can be obtained without
patients knowing they are being observed. While pharmacy benefit plans have begun sharing
these data with clinicians in some settings, they are still not readily available for most
clinical encounters and are almost never provided at the point-of-care.
Electronic adherence monitoring is widely regarded as the gold standard for measuring
medication adherence in research settings. The most common type of monitors are
comprised of special pill caps embedded with an electronic chip that records the date and
time when the cap is twisted open. Other versions include pillboxes that record the date and
time when each bin is opened and closed. A recently approved system, known as Proteus,
records the date and time when a pill enters the stomach. In this system, pills are
compounded with a 1mm silicon-based sensor that releases a signal to a patch worn on the
patient’s arm when the sensor comes into contact with stomach acids. The advantage of
electronic monitoring is that it allows for tracking not just the number of pills taken, but the
intervals between doses and hence can measure whether pills are taken on a day-to-day
basis. Electronic monitoring still has limitations. Foremost, it requires adherence to the
electronic monitoring system which can disrupt the usual manner in which patients take their
medications. For example, a patient who takes their complex medication regimen from a
non-electronic pillbox may feel hassled or confused by having to concurrently use an
electronic pill bottle to track adherence to one of their cardiovascular medications. In
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response, patients may either decline to use the electronic system or may take some pills in
an unmonitored fashion such that the number of pill container openings will not reflect the
number of pills ingested. Another limitation of electronic monitors is that, in contrast with
pharmacy refill data, they serve as reminders that adherence is being observed which may in
turn influence adherence behaviors. Finally, electronic monitors are not yet widely linked
with clinical care pathways or covered by health insurance plans such that it is difficult for
clinicians to use them to track adherence outside of research settings.
Gaps in Knowledge
Significant questions remain regarding the optimal tool for measuring medication adherence.
In the case of self-report instruments, few data exist pertaining to the head-to-head validity
of one instrument versus another. Self-report tools that have been validated in one
population (e.g., general medicine patients) may not be appropriate for another (e.g., elderly
patients with cognitive deficits). Further, while some studies suggest that asking about a
longer time period leads to more accurate measurements, the optimal recall period is not
clear. The lack of a high-quality objective gold-standard measure of adherence has
complicated the identification of an ideal self-report measure. Nevertheless, given their ease
of use, an imperfect measure may be better than no measure and future studies are warranted
to assess whether systematically integrating these instruments into clinical pathways as a
means of screening for non-adherence has any beneficial effect on health outcomes.
With respect to pharmacy refill data, organizations such as the International Society of
Pharmacoeconomics and Outcomes Research have sought to develop standard definitions of
adherence3, yet, the optimal pharmacy refill measure of adherence remains elusive and a
worthy topic for future research.29 The increasing availability of automatic refills via mail-
order pharmacies threatens the validity of pharmacy refill data as the passive receipt of
refills may less clearly reflect pill-taking behavior. The increasing number of low-cost
generic medications being filled from large pharmacy chains such as Walmart and Target
without claims being sent to pharmacy benefit plans is also making it more difficult to
obtain complete refill data.30 For now, combining refill data with complimentary measures
of adherence (e.g., day-to-day electronic adherence or self-reported adherence) may best
capture the full extent to which patients are adherent. Pharmacy refill data will help confirm
that patients remain engaged in at least some amount of prescribed medication use, and self-
reports or electronic monitoring can measure how well patients are executing regimens on a
day-to-day basis.
A major opportunity relevant to the measurement of medication adherence has been
technological advances in electronic medication monitors. Until recently, patients had to
return electronic monitors to researchers or clinicians in order for the adherence information
to be uploaded from the device. Yet, the newest versions of these devices can automatically
transmit adherence data via telephone lines or wirelessly using cellular technologies such
that medication adherence can be measured remotely and unobtrusively by clinicians or
family members. One can imagine a scenario in which electronically measured adherence
becomes a standard piece of data that is integrated into the medical record, monitored
outside of the confines of the in-person clinic visit, and available in real-time.31 If a patient’s
adherence drops below a certain level, it could trigger a phone call from a care manager or
health coach who could seek to problem-solve with a patient how to address the drop in
adherence. In the meantime, significant gaps in knowledge remain regarding the
acceptability of these devices to patients, the feasibility of integrating their use into the
clinical work-flow, and their cost-effectiveness if adopted for wide-spread use.
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Reasons for Poor Medication Adherence
A growing body of research has sought to understand reasons for non-adherence to
cardiovascular medications.29 One approach to grouping reasons is to place them into
patient, provider, health system, and environmental categories (Figure 1). Patient-level
reasons include characteristics such as lack of social support, concerns about medications,
and psychological, cognitive, and medical vulnerabilities. Studies that have directly
surveyed patients to understand reasons for poor medication adherence have shown that
among the patient-level factors, psychological disorders like depression and post-traumatic
stress disorder are consistently among the most strongly associated.32 Provider-level reasons
include factors such as the manner in which clinicians communicate with their patients and
the extent to which clinicians favor simpler dosing schedules.33 Lack of patient-centered
communication, in particular, has been associated with worse adherence. Health system
reasons include aspects such as the cost of drug co-pays and access to follow-up care.
Environmental reasons relate to more distal influences than the health system and can range
from neighborhood characteristics that disrupt easy access to medication refills to media
reports that raise concerns about medications.
Some studies have sought to understand reasons for non-adherence by dividing them into
unintentional (e.g., forgetting to take medication) and intentional (e.g., intentionally
skipping medications) categories.9 Yet, studies have shown that many of the factors that
underlie intentional non-adherence also play a role in unintentional non-adherence. For
example, patients who have more concerns about medications or perceive them to have low
importance are more likely to be both less conscientious (i.e., forgetful) about taking them
and to intentionally skip doses at times. In such patients, interventions directed at decreasing
unintentional medication non-adherence by focusing on reminders without addressing
medication beliefs may not be effective. Hence, researchers and clinicians should be
cautious in applying distinctions between intentional and unintentional non-adherence.
Investigators have also conceptualized reasons for poor medication adherence as predictors
and barriers. Predictors of adherence encompass patient factors like age, gender, or income
level that may help explain subsequent medication adherence. Predictors include factors that
can be used to identify patients most in need of adherence interventions, but that cannot
necessarily be directly modified. We performed a systematic review of predictors of
adherence to statins, and identified a U-shaped association between age and adherence – that
is, the oldest (≥70 years) and youngest (<50 years) patients had lower adherence than the
middle-aged (50–69 years).34 Similar to the findings of other reviews of predictors of
cardiovascular medication adherence, we also found that adherence was significantly lower
in women, in those with lower incomes, in those with higher prescription copays, and in
cases when statins were prescribed for primary prevention. Yet, despite these significant
associations, these predictors explained only a small proportion of the variability in
medication adherence. Hence, consistent with the conclusions found in other papers,
established predictors of adherence are often insufficient to identify individual patients who
are likely to be non-adherent, and they should be used cautiously as a means of targeting
high-risk populations.35
Another approach to understanding reasons for non-adherence is to focus on barriers. In
contrast with predictors of adherence, barriers are restricted to potentially modifiable factors
that physicians and/or the health care system can attempt to overcome to reduce medication
non-adherence. A well-accepted conceptual model for understanding barriers to medication
adherence organizes them into those that stem from interactions between 1) the patient and
their health providers, 2) the patient and the health care system, and 3) health providers and
the health care system.36 We empirically tested components of this model in a cohort of
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stroke survivors from underserved urban communities in New York City and found that
among nine potential barriers, only two were associated with poor medication adherence: 1)
high concerns about medications (e.g.: worry, disruption, long-term-effects, dependence)
and 2) perceived discrimination by the health system as a result of race, ethnicity, education,
or income.
Studies that have used qualitative methods to understand reasons for non-adherence to
cardiovascular medication have confirmed the importance of patients’ concerns about
medications as a key barrier.37,38 Qualitative studies have also revealed that patients’ beliefs
about the etiology and consequences of their cardiovascular illness may diverge
substantially from physicians’ medical models. Specifically, for many patients, the
asymptomatic nature of many cardiovascular diagnoses (e.g., hypertension,
hypercholesterolemia) calls into question the need for everyday medications that do not
provide any benefit that they can feel.
For the practicing clinician, understanding reasons for non-adherence is a fundamental part
of the art of medicine. The list of potential reasons for non-adherence is broad, and many of
them may only be uncovered through patient-centered, collaborative communication that
takes place over a series of clinical visits. Many patients may be embarrassed to admit that
they are having trouble affording medications. Others may not have insight into the manner
in which mild cognitive impairments or psychological symptoms are playing a role. To
identify reasons for non-adherence, clinicians should seek to engage patients in a non-
judgmental fashion and should keep a broad differential, carefully assessing problems
affording medications, medication beliefs, cognitive impairment, and psychological
symptoms when reasons are not easily ascertained. Clinicians may also reach out to social
supports to both gain a greater understanding of issues relevant to non-adherence and to
potentially find resources that can reinforce clinician-directed efforts to reduce non-
adherence.
Gaps in Knowledge
There continues to be interest in increasing the understanding of reasons for poor adherence
to as these reasons may provide the basis for novel adherence interventions. Given the
complexities that underlie non-adherent behavior, future studies will benefit from
considering ecological approaches (e.g., obtaining daily patient diaries) that can account for
multiple levels of mechanisms and their potential interactions over time. In some cases, non-
adherence may only manifest when there is an interaction between underlying
vulnerabilities. For example, in a study of adherence in HIV patients, depression, alone, was
not associated with medication adherence overall. However, depression was strongly
associated with non-adherence during stressful periods that followed major life events.39
These types of studies may benefit from technological advances in measurement tools (e.g.,
smartphone diaries, electronic medication monitors) as well as expansion and linkage of
databases of patient records with pharmacy refill data.
Future studies should also explore novel paradigms that can contribute to our understanding
of non-adherence. For instance, given the importance of health beliefs to adherent behavior,
a more thorough investigation of how communication of health information affects
knowledge transfer and subsequent adherence is warranted.33 As media and internet sources
of health information continue to proliferate, and with the increasing focus on full disclosure
of all possible rare adverse effect of medication treatments, it is important to examine
whether information overload and over-emphasis of negative effects of cardiovascular drugs
is contributing to non-adherence.40
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While patients’ with negative beliefs about medications are at risk for non-adherence, these
beliefs still explain a small portion of the variation in adherence between patients. In
addition, many patients who believe in the importance of cardiovascular medications are still
non-adherent. An established social psychological theory known as terror management
theory may provide another new paradigm for understanding medication adherence and the
frequent discordance between beliefs about medications and pill-taking behavior. This
theory posits that human behavior is strongly motivated by an unconscious fear of
mortality.41 According to this formulation, it is possible that cardiovascular medications
function as unconscious reminders of mortality, and that a large part of medication non-
adherence is due to patients’ efforts to avoid these reminders even though, consciously, they
perceive the medications to be important. Future studies may test this theory by using
implicit association tests that assess the extent to which patients have unconscious
associations between cardiovascular medications and mortality and then determining
whether patients with increased negative associations have lower adherence.
Another emerging field for increasing our understanding of the etiology of poor medication
adherence comes from social network theory.42 In contrast with conventional studies of
determinants of health behavior that emphasize characteristics of individual patients, social
network studies emphasize the interconnectedness of multiple individuals and characterize
the web of social relations between these individuals. There are several reasons to expect
that there will be an association between social network characteristics and medication
adherence among the members. First, medication adherence has previously been associated
with social support, and social support is one of the mechanisms by which social networks
exert their effect. Second, the social network may act as a conduit for ideas about
medications. Third, members of one’s social network may share risks for medical conditions
as a result of shared genetics and environment, and hence, are likely to share ideas about the
behaviors necessary to control these conditions. If the social network’s concerns embrace
the medical issues and medication adherence, then it may be a powerful medium through
which to disseminate adherence interventions.
Approaches to Improving Medication Adherence
In response to the considerable morbidity, mortality, and health care costs associated with
poor medication adherence, researchers have tested numerous interventions to improve
adherence (Table 2).43 The preponderance of these interventions have been directed at
overcoming barriers at the patient and provider level. These include enhanced counseling
through techniques such as motivational interviewing, reminder telephone calls, decision
aids, simplification of drug regimens and the development of combination pills, special
medication packaging, increased education about medications and the disease, and enhanced
care for depression. In one successful cardiovascular medication adherence intervention that
sought to overcome patient-provider barriers, patients were randomized to a pharmacy care
program that involved standardized medication education, regular follow-up by pharmacists,
and medications dispensed in time-specific blister packs versus usual care.44 Following the
start of the intervention, adherence increased from 61% to 97% and there were concomitant
improvements in blood pressure and lipid control.
Several interventions have been directed at patient-health system barriers. Thus far, these
have been directed at reducing or eliminating the cost of medications. In one such trial,
investigators randomized survivors of MI to receiving secondary prevention medications at
no cost versus the usual cost of their drug plan.45 They found that over the course of the
intervention, adherence was poor in both groups, ranging from 35% to 49% in the usual cost
group and 41% to 55% in the free medication group (only 4–6% higher). Although the
intervention did not have an effect on the primary outcome – first major vascular event or
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revascularization – the rate of total major vascular events or revascularization was slightly
reduced and the elimination of copayments did not increase total health care spending.
Hence, even though eliminating copayments did not have a dramatic impact on adherence,
this trial demonstrated that eliminating out-of-pocket medication costs may be a viable
component of future adherence interventions.
Several interventions have been specifically designed to address barriers between providers
and health systems. Some examples include providing clinicians with increased time to
address non-adherence during clinical visits. Other approaches include providing clinicians
with access to adherence data being collected by pharmacy refill databases.
Gaps in Knowledge
Apart from straight-forward adherence interventions that address out-of-pocket medication
costs, successful adherence interventions are complex, costly, and require multiple
components. Further, the vast majority produce modest improvements in adherence
(adherence only improves 4% to 11%), few are proven to improve health outcomes, and
even fewer have been tested for lasting benefits.46 Moreover, most interventions are directed
at only one health condition, and little is known about the effectiveness of any interventions
on improving adherence to medications for multiple concurrent medical conditions.
Accordingly, the consensus of systematic reviews is that there is a pressing need for
innovative approaches to develop medication adherence interventions.43
One approach to developing novel adherence interventions will be to improve upon our
ability to accurately measure adherence and to test the benefits of incorporating validated
tools such as electronic monitoring into clinical practice. Providing this information at the
time of clinical visits will help clinicians more accurately identify non-adherence which is a
pre-requisite for deciding whether to focus efforts on titrating medications or counseling
about adherence.
Another approach may be to develop new approaches to counseling patients to either
prevent or reduce non-adherence. Insights from disciplines like health psychology and
cognitive theory can be utilized to identify strategies to modify common misperceptions
about risks and benefits of important cardiovascular medications. Psychologists may also
help us develop counseling techniques that decouple unconscious associations between
medications and mortality. We may learn that counseling strategies that emphasize the
adverse consequences of missing doses are counterproductive. Yet another approach may be
to develop counseling strategies that help patients form stronger habits for pill-taking
behavior such that the behavior becomes more automatic and less susceptible to day-to-day
changes in motivations and intentions.47
There is strong evidence that reducing the frequency of dosing per day and the total number
of pills per day can improve medication adherence. Hence, yet another approach to
improving adherence may be to maximally simplify cardiovascular drug regimens by
combining medications from three or more drug classes (e.g., aspirin, statin,
antihypertensives) into a single daily “polypill”. Although one of the rationales for the
polypill is to ensure increased prescribing of risk-reducing medications, the other rationale is
that the simpler drug regimen is will lead to improved adherence. This hypothesis remains to
be formally tested and there is a possibility that the strategy may have the opposite effect as
a side-effect from a single component of the polypill may lead to missing doses from the
entire regimen.48
From a health system perspective, an exciting area is leveraging insights from behavioral
economics to inform adherence interventions.49 One approach might be to provide financial
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incentives for better adherence behavior. Kimmel and colleagues tested whether a lottery-
based incentive intervention could improve adherence to warfarin as a means of improving
anticoagulation control. Participants in the intervention were entered into a lottery each day
in which they could win from $3 to $100, but were only eligible to collect their winnings if
their adherence was confirmed based on electronic measurement. In this small pilot trial of
100 participants, the financial incentive based intervention did not significantly improve
anticoagulation in the overall group, but did result in improved control amongst a subgroup
of patients with lower anticoagulation control prior to enrollment suggesting that this
approach is still deserving of additional research.50
Finally, the social network may provide another powerful tool for adherence interventions.
With the newest versions of electronic medication monitors, we can now test the effect of
sharing objective adherence information with members of the social network. When low
adherence is detected, network members may be activated to increase social support for non-
adherent members by, for example, helping patients refill prescriptions or calling with
reminders to take pills. The social network may also prevent poor adherence as knowing that
one’s adherence will be made available to one’s close contacts may exert social pressure to
maintain good adherence. A potential advantage of this social network approach is that it
can operate without the need for additional health care resources as the social network,
rather than health care professionals, will be the ones to intervene.
A key to success for future interventions may lie in learning how to target the right
intervention at the right patient. Thus far, adherence interventions tested in clinical trials
have assigned patients to a variety of treatments regardless of a patient’s personal barriers.
Yet, non-adherence arises out of a complex set of barriers, and the pattern of barriers differs
between patients. For example, high drug costs may be a major barrier in a patient without
prescription insurance but not in another with full prescription coverage. Similarly, while
helpful in some patients, a chronic disease education intervention may not be effective in
patients who already have a good understanding of their disease. In contrast, a targeted,
tailored approach to an adherence intervention comprised of first identifying non-adherence
using validated methods, then determining a patient’s individual-level barriers, then
matching intervention components to these barriers may be more effective than providing all
patients within a group the same intervention.
Summary and Conclusions
Medication taking is an incredibly complex health behavior influenced by numerous factors,
many of which are still just beginning to be understood. From the clinician’s perspective, we
have learned that key aspects of optimizing adherence include keeping non-adherence on the
agenda, asking about it in as non-judgmental a manner as possible, and remaining mindful
that there are few definite predictors of who will be non-adherent so it is best to directly ask
patients. When clinicians do identify non-adherence, being mindful of patient-centered
communication and exploring patients’ concerns about medications may be key factors for
improving adherence. In the meantime, clinicians can make efforts to simplify regimens as
much as possible, prescribe medications with low out-of-pocket costs, make it easy to obtain
refills, encourage adherent habits, enlist social supports when possible, and recommend
additional tools such as pill boxes, electronic pill bottles with alarms, or other organizing
systems to make it easier for patients to remain adherent to their medications on a day-to-
day basis.
From the point of view of the cardiovascular researcher, there continue to be an abundance
of opportunities to contribute to the field of adherence research. Increasing our
understanding of optimal cutpoints for defining non-adherence; more precisely determining
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the extent to which medication adherence specifically contributes to adverse health
outcomes; improving techniques to measure adherence; applying novel paradigms to
understand non-adherence, and developing innovative adherence interventions are all
promising areas for future research.
The problem of poor medication adherence is unlikely to go away anytime soon, and if
anything is likely to grow larger as the population ages and additional medications are
discovered that can alter the course of chronic cardiovascular disease. Given the large scope
of the problem, both in terms of adverse health impact and health costs, researchers and
clinicians might join forces to raise awareness of this issue for key stakeholders in the health
system including government, research funders, health insurers, and the pharmaceutical
industry. On a promising note, in 2012, the Centers for Medicare and Medicaid Services
added medication adherence (as measured by pharmacy refills) as a quality measure that is
tied to payment incentives for Medicare Advantage plans. Although the implications of this
policy remain to be tested, such policies may help to align incentives to support investments
in adherence interventions in the future.
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